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Background: Accidental intravenous exposure to bupivacaine is highly cardiotoxic and may lead to death. Positive
inotropic agents are usually utilized in resuscitative efforts. We have compared the efficacy of levosimendan, a novel
inotropic agent, with dobutamine and their combination in a rat model of bupivacaine intoxication.
Methods: Twenty-eight male Wistar albino rats weighing between 250-300 g were divided into these four groups:
control (C), levosimendan (L), dobutamine (D) and dobutamine+levosimendan (D+L). Bupivacaine was administered
at a dose of 3 mg/kg/min until cardiac arrest occurred or for 120 min. ECG, heart rate, blood pressure, arterial blood
gases, and end tidal CO2 levels were monitored. Levosimendan was administered as a bolus of 12 μg/kg for 10 min
and continued as an infusion at 0.3 μg/kg/min. Dobutamine was infused at a dose of 3 μg/kg/min. The time
required for a 50% and 75% decrease in heart rate and blood pressure with a total time to cardiac arrest and
bupivacaine dose for obtaining cardiac arrest were analyzed.
Results: Time periods for heart rate reductions of 50% and 75% were significantly longer in groups L (903, 1198 s),
D (984, 1542 s) and L+D (1705, 3152 s) compared with the control group (345, 538 s p < 0.001). Median times to
mean blood pressure reductions of 50% and 75% were 399 - 504 s in the control group, 1005 -1204 s in group L,
685 - 1009 s in group D and 1544- 2982 s in group L+D, and the difference was significant compared with the
control group. Median time duration to asystole was 703 s in the control group compared with 1385 s in group L,
1789 s in group D and 3557 s in group L+D. Time to cardiac arrest was significantly higher in all 3 study groups. It
was also significantly higher in the L+D group compared with both groups L and D separately.
Conclusion: A combination of dobutamine with levosimendan significantly increased survival times in this
bupivacaine-induced toxicity rat model compared with the control, levosimendan, and dobutamine groups.
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Bupivacaine is one of the most cardiotoxic local anesthetic
agents. Despite its known adverse effects on the heart, it is
widely used by anesthesiologists and surgeons for localized
procedures and nerve blocks [1]. Although it is usually a
safe agent that can be used without any adverse effects at
recommended doses, there are reports in the literature
that accidental intravenous administration of bupivacaine
during epidural or peripheral nerve blocks do exist and
lead to cardiac arrest, which is refractory to resuscitation
in some patients [2].* Correspondence: fikret.maltepe@deu.edu.tr
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reproduction in any medium, provided the orIntravenous administration of local anesthetics and par-
ticularly bupivacaine results in reduced cardiac contractility
arrhythmias and hypotension [3], which can lead to ven-
tricular tachycardia, fibrillation, asystole, and complete
heart block in humans [4]. Resuscitation after bupivacaine-
induced cardiovascular collapse usually involves the use of
sympathomimetic agents to restore coronary circulation,
and adrenaline, isoproterenol, dopamine, dobutamine, and
amrinone, a phosphodiesterase inhibitor, have been evalu-
ated in animal models with variable results [4]. Current
guidelines recommend the utilization of intralipid solutions
in cases of cardiac arrest following local anesthetic toxicity
with bupivacaine [3,5]. However, the underlying mecha-
nisms of this novel therapy have not been fully understood.
Therefore, it is necessary to search for new drugs or drugral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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life-threatening medical condition.
Levosimendan is a calcium sensitizer, which binds to
cardiac troponin C and increases the calcium sensitivity
of myocytes. Levosimendan increases contractility of the
cardiac muscle without increasing intracellular calcium
[6]. Levosimendan is currently indicated for the treat-
ment of chronic heart failure and has been proven bene-
ficial in certain acute cardiotoxic events [7-10].
Therefore, we have hypothesized that levosimendan
may help resuscitative efforts after accidental exposure
to intravenous bupivacaine. To determine its possible
use following cardiovascular collapse after bupivacaine-
induced cardiotoxicity, we have evaluated the effects of
levosimendan and dobutamine treatment in an animal
model of acute bupivacaine toxicity. The primary out-
come variable was duration to cardiac arrest.
Methods
This study was approved by our institutional review board
for animal studies (Dokuz Eylul University School of Medi-
cine (DEUSM) Local Animal Experiments Ethical Commit-
tee 24.12.2010, The number of protocol: 75-2010, Yilmaz
O), and the experiments were performed at the Dokuz
Eylül University multidisciplinary animal laboratory. In all,
28 male Wistar albino rats weighing between 250-300 g
were used. Rats were anesthetized with an intraperitoneal
injection of Uretan® (Sigma Chemical Company, St. Louis,
MO, USA) at a dose of 1 g/kg. The animals were placed
in a supine position with tapes, and a tracheostomy was
performed with a 16-G venous cannula. Two 20-G venous
cannulae were placed in both tail veins, and 0.9% saline
was administered at a bolus dose of a 0.5 ml and continued
as an infusion at 2 ml/h. A 26-G catheter was placed in the
right carotid artery for arterial pressure monitoring; a flush
solution containing 100 U/ml of heparin was used for this
purpose. Vecuronium (Norcuron®, Organon, Netherlands)
was administered at a dose of 0.03 mg/kg, and the animals
were connected to a small animal ventilator (Kent Scien-
tific Pressure Controlled Ventilator, Norfolk, CT, USA).
The ventilator was set at room air with a tidal volume of 8
ml/kg and rate of 55/min. The end tidal carbon dioxide
level was kept between 25-30 mm Hg (Anesthetic Gas
Monitor Type 1380, Brüel&Kjaer, Denmark). The animals
were kept at 37°C. Electrocardiogram was monitored thru
needle leads placed in all four extremities, and the ECG
and blood pressure waveforms were recorded with a
Biopac mp 35 polygraph recording system (Biopac System,
Inc., Santa Barbara, CA, USA).
After a 15-min stabilization period, baseline heart rate,
systolic, diastolic and mean arterial pressure, QRS dur-
ation and arterial blood oxygen saturation, pH, and carbon
dioxide levels were recorded. An intravenous infusion
of bupivacaine (Marcaine heavy, Astra Zeneca Istanbul,Turkey) at a 3 mg/kg/min dose was initiated after the
stabilization period and continued until either cardiac
arrest occurred or an infusion duration of 120 min was
reached. Elapsed time from the start of bupivacaine infu-
sion to cardiac arrest was defined as the major endpoint of
the study.
Study animals were divided into the following four treat-
ment groups: control, levosimendan, dobutamine, and
dobutamine+levosimendan groups. Infusion of the study
drugs was initiated at the first sign of cardiotoxicity, which
was determined as a 20% increase in the duration of the
QRS complex.
Control group (n = 7), Group C: No additional medica-
tion was given; only a saline infusion was maintained.
Levosimendan group (n = 7), Group L: At the first sign
of cardiotoxicity, levosimendan (Simdax® Abbott, USA)
was started from the second tail vein catheter at a bolus
dose of 12 μg/kg for 10 min, and the infusion was contin-
ued at 0.3 μg/kg/min until cardiac arrest.
Dobutamine group (n = 7), Group D: At the first sign of
cardiotoxicity, dobutamine (Eczacibasi-Baxter, Turkey) at
a dose of 3 μg/kg/min was started and continued until car-
diac arrest.
Dobutamine+Levosimendan group (n = 7), Group D+L:
At the first sign of cardiotoxicity, levosimendan was given
as a bolus of 12 μg/kg for 10 min and was followed by
an infusion of 0.3 μg/kg/min. A dobutamine infusion was
simultaneously started at a dose of 3 μg/kg/min and con-
tinued until cardiac arrest.
Blood pressure, ECG, and heart rates of the subjects
were recorded continuously. Time durations for 50% and
75% decreases in mean blood pressure and heart rate as
well as the total time to cardiac arrest were recorded.
Power analysis
The primary outcome of this study was the time that
elapsed from the start of bupivacaine infusion until asys-
tole. In a previous report comparing saline and clonidine
pretreatment in the prevention of bupivacaine-induced
cardiotoxicity in rats, the investigators used the same pri-
mary outcome that was used in this study [9]. In this
study, asystole time was determined 546 ± 82 s in the
bupivacaine+saline group [9]. Using this data and the de-
tection of a 20% change in the asystole time with an α
error of 0.05 and a power of 80%, it was calculated that
the sample size should be at least seven rats per group.
For 2 by 2 analysis when p value is taken as 0.01 the study
power is calculated less than 80%.
Statistical analysis
The results are presented as medians because the number
of subjects was too small to allow a normal distribution.
Group comparisons determining homogeneity were made
using the Kruskall-Wallis test, significance was accepted at
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binary fashion with study groups compared with the con-
trol group using the Mann-Whitney U test and signifi-
cance was calculated at a p value less than 0.0083 with
Bonferroni correction. The study data were analyzed using
version 11.5 of SPSS software.
Results
The baseline variables of the subjects in all four groups
were similar. There was no difference in relation to
weight, heart rate, blood pressure, QRS width, arterial
blood pH, pO2 and pCO2 values (Table 1).
The infusion time to first sign of cardiotoxicity, which
was a 20% increase in the QRS duration, was statistically
similar in all four groups. Hemodynamic changes, arrest
times, and total lethal dose of bupivacaine are presented
in Table 2.
The median times to a 50% and 75% decrease in heart
rate were significantly longer in groups L (903-1198s),
group D (984, 1542 s) and L+D (1705, 3152 s) compared
with the control group (345, 538 s p < 0.05). There was
also no significant difference between groups D and L+D
but the study was under powered for pairwise analysis.
Median time duration for a decrease in mean blood
pressure of 50% and 75% was also longer in all three study
groups compared with the control group (399, 504 s). It
was longest in the L+D group [1544, 2982 s, followed by
group L (1005, 1204 s) and group D (685, 1009 s)]. While
comparison between group L+D and group L and group
D reached significance, the comparison between group D
and group L did not reach significance but the study was
underpowered in this regard.
Three subjects in the B+L group did not develop car-
diac arrest during the 120-min study duration; all other
subjects eventually developed asystole. The median time
duration to asystole was 703 s in the control group com-
pared with 1385 s in group L, 1789 s in group D and
3557 s in group L+D. Time to cardiac arrest was signifi-
cantly higher in all three study groups. It was alsoTable 1 Baseline values of the study subjects are given as me
Groups Control Levosim
Weight (g) 286 (260-313) 219 (26
Heart rate/minute 348 (238-427) 349 (30
Systolic blood pressure (mmHg) 113 (105-129) 122 (10
Diastolic blood pressure (mmHg) 67 (52-86) 78 (54
Mean blood pressure (mmHg) 82 (70-100) 93 (71
QRS width (s) 0.023 (0.022-0.025) 0.022 (0.0
Arterial blood pH 7.33 (7.14-7.39) 7.31 (7.2
Arterial blood pO2 (mmHg) 182 (118-216) 148 (10
Arterial bood pCO2 (mmHg) 30 (21-39) 29 (28
Comparison between four groups showed no statistically significant difference.significantly higher in the L+D group compared separately
with both groups L and D. The total infused dose of
bupivacaine showed a similar pattern in all three groups
that was significantly higher than in the control group,
and also was higher in the L+D group compared with
groups L and D.
Discussion
The results of this study have demonstrated that both
levosimendan and dobutamine prolong the time for car-
diac arrest development after bupivacaine-induced
cardiotoxicity.
Deleterious effects of accidental intravenous adminis-
tration of bupivacaine leading to severe cardiovascular
collapse and shock are well documented [11-13]. Various
agents have been evaluated for alleviating the cardiotoxic
effects of bupivacaine in both animal studies and human
case series. Experimental treatment protocols have in-
cluded amrinone, isoprotrenol, insulin, clonidine, adren-
alin, and phenylephrine. Currently only dobutamine and
lipid infusion are generally recommended [14-24]. Des-
pite all resuscitative efforts with dobutamine and lipid
infusion treatment, accidental intravenous bupivacaine
exposure can be fatal, and newer treatment options may
prove helpful [3].
Levosimendan has proven beneficial effects on cardiac
dysfunction following cardiac surgery, myocardial infarc-
tion, cardiac resuscitation, or sepsis [25-31]. Despite its
growing use in cardiac failure patients, levosimendan was
evaluated in only two previous animal studies for treating
experimental cardiotoxicity caused by local anesthetic
agents. In one study with ropivacaine, a levosimendan in-
fusion caused a marked improvement in heart rate, as well
as generated pressure and cardiac output, compared with
a normal saline infusion in isolated pig hearts [32]. These
promising results led to another study involving anesthe-
tized pigs that evaluated the effect of levosimendan on
bupivacaine-induced cardiotoxicity [33]. In this random-
ized study, 20 pigs received a bupivacaine infusion at adian and minimum and maximum
endan Dobutamine Dobutamine+Levosimendan
8-336) 292 (269-338) 295 (255-315)
9-400) 381 (230-456) 343 (233-481)
5-131) 112 (94-150) 117 (96-134)
-86) 72 (48-100) 65 (45-87)
-101) 81 (63-116) 84 (67-97)
19-0.026) 0.022 (0.019-0.026) 0.023 (0.020-0.026)
3-7.42) 7.36 (7.21-7.38) 7.34 (7.24-7.39)
5-219) 153 (128-288) 149 (118-288)
-38) 30 (26-38) 33 (24-42)
Table 2 Results of the control group with the 3 study groups
Study groups Control Levosimendan Dobutamine Dobutamine+Levosimendan
Initial QRS > 20% (s) 162 (101-342) 173 (103-403) 153 (105-410) 159 (90-432)
Initial arrhythmia (s) 203 (129-549) 455 (153-850) 448 (249-1367) 310 (97-567)
Heart rate < 50% (s) 345 (214-583) 903* (301-1848) 984 *(672-2814) 1705 †* (1039-3009)
Heart rate < %75 (s) 538 (353-961) 1198* (358-7014) 1542 * (895-4092 3152 †* (1747-6519
Mean arterial pressure < %50 (s) 399 (245-665) 1005* (243-1592) 685* (514-1992) 1544 †* (874-3003)
Mean arterial pressure < %75 (s) 504 (381-814) 1204* (298-6028) 1009* (698-4013) 2982 †* (1542-6897)
Cardiac arrest time (s) 703 (403-1049) 1385* (412-6552) 1789 * (944-4742) 3357 †* (1825-7200)
Total Bupivacaine dose (μg) 8.48 (5.03-13.11) 17.62 * (5.15-90.0) 22.36 * (11.80-59.20) 41.90 †* (22.80-90.0)
Data is given as median with minimum and maximum values.
*p < 0.05 compared to the control group, †p < 0.008 for pairwise comparison of all 4 groups.
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pressure. The study group received 80 μg/kg levosimendan
for 10 min followed by an infusion of 0.7 μg/kg/min. Al-
though cardiac output, ejection fraction, and stroke power/
end-diastolic volume measurements showed rapid im-
provement with levosimendan, there was no time-group ef-
fect difference in overall recovery and mortality. Heart rate
was significantly higher in the levosimendan group, and this
was interpreted as a possible sign of improved recovery
with levosimendan [33].
Encouraging results from the isolated pig heart and pig
animal studies have led us to design our study using a
rat model. In the present study, in contrast to the previ-
ous study, we continued the bupivacaine infusion until car-
diac arrest. Another difference was that we also compared
levosimendan infusion with dobutamine and a dobutamine+
levosimendan combination treatment. The reasoning being
that in clinical situations with severe cardiotoxic effects, these
drugs would most likely be used in combination to revive
the patient. A bupivacaine infusion dose of 3 mg/kg/min was
chosen because a previous study in rats demonstrated rapid
cardiovascular collapse with a similar dose [34].
Our results did show a consistent trend in improved sur-
vival times with a levosimendan infusion. In the group that
received levosimendan infusion alone, infusion durations
leading to a 50% and 75% decrease in both heart rate and
mean blood pressure were longer compared with the con-
trol group, but the differences did not reach statistical sig-
nificance. Survival times and the mean bupivacaine dose
required for cardiac arrest did show a statistically signifi-
cant improvement. Dobutamine infusion alone showed a
similar effect on blood pressure and heart rate reduction
times, and the effect on heart rate showed statistical signifi-
cance. Survival time and total bupivacaine doses were also
significantly higher compared with the control group but
showed no difference compared with the levosimendan
infusion group.
A combination of levosimendan with dobutamine
showed a marked improvement in all study endpoints
except time to first arrhythmia. These differences reachedstatistical significance for time durations for 50% and 75%
decreases in both mean blood pressure and heart rate
compared with the control group and also compared with
the levosimendan and dobutamine groups. Three rats in
the dobutamine+levosimendan group reached the 120-
min termination point without developing cardiac arrest.
The mean time to cardiac arrest and the mean infused
dose of bupivacaine was more than fourfold higher com-
pared with the control group, and these parameters were
significantly improved compared with the dobutamine
and levosimendan groups.
It is logical to assume that a combination of dobutamine
and levosimendan would augment their respective inotropic
effect because they affect different steps of the cardiac
myocyte calcium metabolism [35,36]. Levosimendan also has
a vasodilatory effect, but an increase in cardiac output may
have compensated for this vasodilatory effect; our results did
not show a decrease in blood pressure [37]. This vasodilatory
effect may explain why the blood pressure decrease times
did not reach statistical significance in the levosimendan
alone infusion group. Predictably, heart rate was also un-
affected by levosimendan as much as dobutamine.
Our results suggest an improved recovery with
levosimendan in bupivacaine-induced cardiotoxicity.
Dobutamine does have a similar effect, but this im-
provement in recovery can be augmented greatly if
dobutamine is combined with levosimendan. Our study
has shown that dobutamine+levosimendan is safe in
this context, i.e., there was no increased arrhythmogenic
effect. We believe this combination can administered in
patients with acute bupivacaine intoxication and cardio-
vascular collapse because this drug combination is clin-
ically approved for the management of cardiac failure
[26]. Further studies are required to compare the effi-
cacy of levosimendan to lipid treatment for resuscita-
tion following bupivacaine-induced toxicity.
Conclusions
Our study has shown an increased survival time with
both levosimendan and dobutamine infusion following
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with administration of dobutamine and levosimendan to-
gether with survival times significantly longer compared to
all groups. This combination may prove useful in treating
circulatory collapse following bupivacaine toxiticity.
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